The newly approved oral GLP-1 orforglipron (Foundayo) is a distinct non-peptide small molecule with its own independent patent timeline.
By 2008, the manufacturer (Palatin Technologies) halted nasal formulation trials and pivoted to a subcutaneous injection route, which showed fewer cardiovascular side effects
In all, the researchers examined 58,000 people in a semaglutide versus sitagliptin comparison
What the 26-Week Results Suggest The complete week-26 findings were presented at the European Association for the Study of Diabetes meeting in September 2025, but they have not yet appeared as a full peer-reviewed paper
Thyroid hormone is critical for hair growth, and disruptions can worsen hair shedding
The vial is available directly through manufacturer Eli Lilly, starting at $349 per month, cash-pay